GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » Total Liabilities
中文

SIGA Technologies (SIGA Technologies) Total Liabilities

: $57.5 Mil (As of Dec. 2023)
View and export this data going back to 1997. Start your Free Trial

SIGA Technologies's Total Liabilities for the quarter that ended in Dec. 2023 was $57.5 Mil.

SIGA Technologies's quarterly Total Liabilities increased from Jun. 2023 ($22.44 Mil) to Sep. 2023 ($34.24 Mil) and increased from Sep. 2023 ($34.24 Mil) to Dec. 2023 ($57.49 Mil).

SIGA Technologies's annual Total Liabilities declined from Dec. 2021 ($40.41 Mil) to Dec. 2022 ($24.88 Mil) but then increased from Dec. 2022 ($24.88 Mil) to Dec. 2023 ($57.49 Mil).


SIGA Technologies Total Liabilities Historical Data

The historical data trend for SIGA Technologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.78 20.04 40.41 24.88 57.49

SIGA Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.88 21.83 22.44 34.24 57.49

SIGA Technologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SIGA Technologies's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=54.118+(0+3.376
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=57.5

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=254.353-196.859
=57.5

SIGA Technologies's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=54.118+(0+3.376
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=57.5

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=254.353-196.859
=57.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SIGA Technologies Total Liabilities Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


SIGA Technologies (SIGA Technologies) Business Description

Traded in Other Exchanges
N/A
Address
31 East 62nd Street, New York, NY, USA, 10065
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Executives
Evan A. Knisely director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr. director 4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal director 30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky director 35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi director 35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan director C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii officer: Chief Executive Officer 7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire officer: Executive VP & CFO C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas director 35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane director 77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby officer: Chief Scientific Officer SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer director 1100 N GLEBE ROAD, ARLINGTON VA 22201

SIGA Technologies (SIGA Technologies) Headlines

From GuruFocus

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX � (tecovirimat) for Treatment of Monkeypox

By deactivated_deactivated_Ds*** deactivated_deactivated_Ds*** 10-12-2022